NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
23:05
The only anti-war party in Russia has been excluded from the electoral race.
23:00
Over 1,200 Palestinians have been killed in Gaza since the ceasefire with Israel came into effect in October 2025. UN experts warn of the ongoing genocide.
22:55
The Alba Iulia Court of Appeal rejected the proposal for the preventive arrest of prosecutor Radu George Bucurică, accused of crimes related to the illegal possession and use of a lethal firearm.
22:53
Diana Buzoianu announced that the estimates for the operation of Unit 2 at Cernavodă have been revised negatively: "We are in a much gloomier forecast than we were yesterday."
22:47
Ionel Bogdan (PNL) accuses disinformation on TikTok for the attack on an ambulance and requests the hearing of the president of ANCOM in Parliament.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
